AstraZeneca’s Imfinzi Receives Expanded Health Insurance Coverage in South Korea, Including for Bile Duct Cancer
Seoul, South Korea – Beginning March 1, 2026, AstraZeneca’s Imfinzi (durvalumab) will have its health insurance coverage significantly expanded in South Korea, now including treatment for bile duct cancer, in addition to its existing coverage for non-small cell lung cancer and bladder cancer. The decision, made by the Health Insurance Policy Deliberation Committee on February 25th, is expected to dramatically reduce treatment costs for patients and broaden access to this important immunotherapy. This expansion marks a significant step in addressing unmet needs for patients with these aggressive cancers.
The move comes after a series of approvals and expansions for Imfinzi in recent years. Initially approved in December 2019 for the treatment of locally advanced non-small cell lung cancer (NSCLC), the drug has steadily gained traction in the South Korean market. Last November, Imfinzi received approval from the Ministry of Food and Drug Safety for use in treating bladder cancer, a disease where survival rates decline rapidly upon metastasis and treatment options have historically been limited. According to reports from the Yakup Shinmun, Imfinzi is rapidly establishing itself as a key player in the treatment of hard-to-treat cancers.
How Imfinzi Works and Why the Expansion Matters
Imfinzi is an immune checkpoint inhibitor, a type of immunotherapy that works by blocking the PD-L1 protein on cancer cells. This blockade effectively releases the brakes on the immune system, allowing T-cells to recognize and attack cancer cells more effectively. The expansion of coverage to include bile duct cancer is particularly noteworthy, as this cancer has seen limited advancements in treatment options over the past decade. ZDNet Korea reports that no latest drugs have been listed for bile duct cancer treatment in the last ten years, making Imfinzi’s approval a crucial development.
The financial impact of this expanded coverage will be substantial. Prior to the health insurance expansion, the annual cost of Imfinzi treatment for a single patient could reach approximately 118.93 million Korean Won (roughly $90,000 USD, exchange rates fluctuate). With the new coverage, the cost is expected to drop to around 5.95 million Korean Won (approximately $4,500 USD) per year, representing a significant reduction in out-of-pocket expenses for patients. This reduction is based on a 5% patient co-payment.
The Health Insurance Policy Deliberation Committee’s Role
The Health Insurance Policy Deliberation Committee plays a critical role in determining which medical treatments are covered by South Korea’s national health insurance system. The committee’s February 25th decision to expand Imfinzi’s coverage reflects a growing recognition of the value of immunotherapies in treating challenging cancers. The committee’s deliberations considered the clinical benefits of Imfinzi, as demonstrated in clinical trials, as well as the potential economic impact of making the drug more accessible to patients.
According to a statement from the Ministry of Health and Welfare, the expansion of health insurance coverage for Imfinzi is expected to broaden treatment options, extend survival rates, and alleviate the financial burden on patients battling bile duct cancer. Lee Hyung-hoon, Second Vice Minister of Health and Welfare, emphasized the government’s commitment to accelerating policy implementation in response to rapid changes in the medical landscape.
Imfinzi’s Journey to Expanded Approval
AstraZeneca has been actively pursuing the expansion of Imfinzi’s indications through ongoing clinical research. The company’s efforts culminated in the approval for bladder cancer in November 2025 and, now, the health insurance coverage extension for bile duct cancer. This strategic approach has allowed Imfinzi to steadily gain a foothold in the oncology market, offering a new treatment option for patients with limited alternatives.
The approval process involved a thorough review of clinical trial data by the Ministry of Food and Drug Safety, demonstrating the drug’s efficacy and safety profile. The subsequent health insurance coverage decision by the Health Insurance Policy Deliberation Committee further solidified Imfinzi’s position as a valuable treatment option within the South Korean healthcare system.
Looking Ahead: What This Means for Cancer Treatment in South Korea
The expanded coverage for Imfinzi represents a positive trend in South Korea’s approach to cancer treatment. By embracing innovative immunotherapies and making them more accessible to patients, the country is demonstrating a commitment to improving outcomes for individuals battling these devastating diseases. The success of Imfinzi could pave the way for broader adoption of other immunotherapies in the future, further transforming the landscape of cancer care.
The Ministry of Health and Welfare has indicated that it will continue to monitor the impact of the expanded coverage and assess the need for further adjustments to ensure that patients have access to the most effective and affordable treatments available. The next steps will involve ongoing data collection and analysis to evaluate the long-term benefits of Imfinzi in real-world clinical settings.
This development underscores the growing importance of immunotherapy in the fight against cancer and highlights the crucial role of health insurance policies in ensuring equitable access to these life-saving treatments. As research continues and new immunotherapies emerge, It’s likely that we will see further expansions in coverage and improved outcomes for cancer patients in South Korea and around the world.
Key Takeaways:
- AstraZeneca’s Imfinzi now has expanded health insurance coverage in South Korea, including treatment for bile duct cancer.
- The expansion is expected to significantly reduce treatment costs for patients, from approximately $90,000 to $4,500 annually.
- Imfinzi is an immunotherapy that works by activating the immune system to fight cancer cells.
- The decision reflects a growing recognition of the value of immunotherapies in treating challenging cancers.
The Health Insurance Policy Deliberation Committee is scheduled to meet again in April 2026 to review additional drug coverage applications. Stay tuned to World Today Journal for further updates on this developing story. We encourage readers to share their thoughts and experiences in the comments section below.
Related reading